Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
Two large pivotal phase III studies demonstrated the efficacy of the tetravalent dengue vaccine (CYD-TDV; Dengvaxia®, Sanofi Pasteur) against all dengue serotypes. Here we present an unprecedented integrated summary of the immunogenicity of CYD-TDV to identify the parameters driving the neutralizing...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Taylor & Francis Group
2017-09-01
|
| Schriftenreihe: | Human Vaccines & Immunotherapeutics |
| Schlagworte: | |
| Online-Zugang: | http://dx.doi.org/10.1080/21645515.2017.1333211 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|